Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

RCN Responds To Publication Of Lord Darzi's Progress Report
Responding to the publication of Lord Darzi"s report, High Quality Care for All: Our Journey So Far, Dr Peter Carter, Chief Executive & General Secretary of the Royal College of Nursing (RCN), said:

Trubion Announces Positive Data From A Phase 1 / 2 Study Of TRU-016 For The Treatment Of Chronic Lymphocytic Leukemia (CLL)
Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced the presentation of encouraging Phase 1 safety and efficacy results following administration of low doses of TRU-016 in heavily pre-treated patients with high-risk genomic factors and relapsed or refractory chronic lymphocytic leukemia (CLL). TRU-016 is the Company"s proprietary anti-CD37 Small Modular ImmunoPharmaceutical (SMIP(TM)) product candidate.
News of the day
Passport Health Of Massachusetts Warns New Englanders, "Exploding Mosquito Population Can Be Deadly, Look For Repellents With At Least 30% DEET!"
Passport Health of Massachusetts, specialists in vaccinations against dread diseases faced by international travelers, is concerned that eastern New England"s wettest spring and early summer in decades can be more deadly than usual.
Diagnostics

Bone Marrow Cell Therapy May Be Beneficial For Patients With Ischemic Heart Disease

The injection of bone marrow cells into the heart of patients with chronic myocardial ischemia (reduced blood flow to some areas of the heart) was associated with modest improvements in blood flow and function of the left ventricle, according to a study in the May 20 issue of JAMA. Bone marrow cell therapy is currently being investigated as a new therapeutic option for patients with ischemic heart disease. Two small-sized studies assessed the effect of this therapy in patients with chronic myocardial ischemia, but with varying results, according to background information in the article. Jan van Ramshorst, M.D., of Leiden University Medical Center, the Netherlands, and colleagues assessed the effect of intramyocardial (within the heart wall) bone marrow cell injection on myocardial perfusion (the flow of blood to the heart muscle) and left ventricular (LV) function in patients with chronic ischemia who were not eligible for conventional treatment. The trial included 50 patients (average age, 64 years; 43 men), who were randomized to receive about 8 injections of either bone marrow cells or placebo solution. At 3-month follow-up, when the two groups were compared, the improvement in summed stress score (a measure of myocardial perfusion) was significantly greater in the bone marrow-cell treated patients as compared with placebo-treated patients. Magnetic resonance imaging indicated that the absolute increase in left ventricular ejection fraction (LVEF; a measure of how well the left ventricle of the heart pumps with each contraction) was significantly larger in bone marrow cell-treated patients. A quality-of-life score increased at 3 and 6 months in bone marrow cell-treated patients, compared with a smaller increase in the placebo group. There was also greater improvement in exercise capacity in the bone marrow cell group. "In summary, the results of this randomized, double-blind, placebo-controlled trial demonstrate that intramyocardial bone marrow cell injection in patients with chronic ischemia is associated with significant improvements in anginal symptoms, myocardial perfusion, and LV function," the authors write. JAMA 2009;301[19]:1997-2004. JAMA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009